CClinicalTrials.gg
CompletedNCT05882383Updated May 31, 2023

Changes of Optical Quality During the Peak of the Covid-19 Pandemic

An observational study in Corneal Wavefront Aberration and SARS-CoV-2, sponsored by Tianjin Eye Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 32 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-31.

Sponsored by Tianjin Eye Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
110
Ages
18 Years to 32 Years
Sex
All
01

Study summary

To explore whether cornea structure, and optical quality are affected by the covid-19 infection.

Read the detailed description

Participants with healthy corneas admitted to Tianjin Eye Hospital from November 25 to January 20, 2022 were followed up . At the end of the follow-up, the investigators recorded in detail whether the patients had undergone real-time reverse transcriptase polymerase chain reaction (covid-19 RT-PCR tests) testing, testing time and results. The presence of PCR-positive during follow-up is considered to be covid-19 infection; PCR-Negative and no symptoms of infection during the follow-up period are considered not infected; participants with symptoms but no PCR test were excluded from the study.Participants were divided into three groups according to the RT-PCR results and the presence or absence of symptoms of infection during follow-up. pentacam (Pentacam HR, Oculus, Wetzlar, Germany) was performed during follow-up and the results were recorded,and the data was statistically managed and compared.

02

Conditions studied

  • Corneal Wavefront Aberration
  • SARS-CoV-2

Browse trials for

Keywords

  • optical quality
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's enrollment of 110 is below the median of 261 across 3,136 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Tianjin Eye Hospital is the lead sponsor of 49 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 32 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

patients admitted to refractive center of Tianjin Eye Hospital

Eligibility criteria

Included Criteria

  1. Best corrected visual acuity (BCVA) ≥ 20/20;
  2. No other eye diseases except myopia and astigmatism;
  3. The cornea was transparent, and there was no cloud or pannus;
  4. No clinical manifestation of Eye disease or systemic disease;

Exclusion Criteria:

  1. corneal disease;
  2. ocular trauma;
  3. Pregnant and lactating women;
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
110 participants (actual)
Patient registry
No

Groups and cohorts

  • Control Group

    unifected with SARS-CoV-2 during follow-up

  • Group A

    uninfected at the first visit, have been infected at the second visit

  • group B

    have been infected at twice visit

06

What researchers measure

Primary outcomes

  1. The value of cornea aberration

    The value of aberration data from pentacam during follow-up were compared, including coma, spherical aberration, defocus, and astigmatism

    Time frame: 1 months

  2. The value of cornea backscatter

    The value of cornea backscatter from pentacam during follow-up were compared, including anterior layer,central layer and posterior

    Time frame: 1 months

  3. The value of cornea thickness

    The value of cornea thickness from pentacam during follow-up were compared, includig the thinnest point, apex of the cornea.

    Time frame: 1 months

07

Study locations

1 site
  • Tianjin Eye Hospital
    Tianjin, Tianjin, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05882383
Lead sponsor
Tianjin Eye Hospital
Responsible party
Sponsor
First posted
May 31, 2023
Start date
Nov 25, 2022
Primary completion
Jan 20, 2023
Completion
Jan 20, 2023
Last update
May 31, 2023

Study contacts

Yan Wang, Prof
study chair · Tianjin eye hosipital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion